Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CYP3A4 Antibodies:
anti-Mouse (Murine) CYP3A4 Antibodies:
anti-Rat (Rattus) CYP3A4 Antibodies:
Go to our pre-filtered search.
Human Polyclonal CYP3A4 Primary Antibody for IHC (p), WB - ABIN514838
Yamashita, Honda, Nio, Nakamoto, Yamashita, Takamura, Tani, Zen, Kaneko: Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. in Cancer research 2010
Show all 3 Pubmed References
Human Monoclonal CYP3A4 Primary Antibody for ICC, FACS - ABIN969512
van Waterschoot, Rooswinkel, Sparidans, van Herwaarden, Beijnen, Schinkel: Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. in Drug metabolism and disposition: the biological fate of chemicals 2009
Show all 2 Pubmed References
Human Polyclonal CYP3A4 Primary Antibody for Func, WB - ABIN2473177
Chirkov YuYu, Tyshchuk, Severina: Guanylate cyclase in human platelets with different aggregability. in Experientia 1990
Show all 3 Pubmed References
Human Polyclonal CYP3A4 Primary Antibody for WB - ABIN269568
Buchanan, Meng, Poulin, Zuccolo, Azike, Gabriele, Baranowski: Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine. in PLoS ONE 2018
Human Polyclonal CYP3A4 Primary Antibody for ELISA - ABIN547650
Choi, Skipper, Wishnok, Tannenbaum: Characterization of testosterone 11 beta-hydroxylation catalyzed by human liver microsomal cytochromes P450. in Drug metabolism and disposition: the biological fate of chemicals 2005
Human Polyclonal CYP3A4 Primary Antibody for FACS, IF - ABIN652422
Okamatsu, Kawakami, Komatsu, Kitazawa, Uno, Teraoka: Functional expression and comparative characterization of four feline P450 cytochromes using fluorescent substrates. in Xenobiotica; the fate of foreign compounds in biological systems 2017
Cow (Bovine) Polyclonal CYP3A4 Primary Antibody for WB - ABIN2784528
Werk, Lefeldt, Bruckmueller, Hemmrich-Stanisak, Franke, Roos, Küchle, Steubl, Schmaderer, Bräsen, Heemann, Cascorbi, Renders: Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. in Clinical pharmacology and therapeutics 2014
Human Polyclonal CYP3A4 Primary Antibody for IF, IHC - ABIN3023346
Wei, Dai, Zhou, He, Yao, Zhao, Guo, Yang: Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression. in Cell death & disease 2018
Human Polyclonal CYP3A4 Primary Antibody for IP, WB - ABIN947776
Fujiwara, Itoh: Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome. in Pharmacology research & perspectives 2014
four binding interactions of aNF to P450 3A4 are suggested by this study, one of which may be newly recognized and which could affect studies of drug oxidations by this important enzyme
We analyzed tacrolimus trough concentrations in 1345 adult EA recipients with two CYP3A5 LoF alleles in a genome-wide association study. Only CYP3A4*22 was identified and no additional variants were genome-wide significant
heterozygous for CYP 3A4*22 partially explained the early-onset and severity of myelosuppression in patient taking Sunitinib for kidney neoplasm
Experimental in silico and in vivo studies confirmed that the original Russian benzodiazepine phenazepam was the substrate of CYP3A4 isoenzyme.
The CYP2C19 phenotype is not predicted by the number of functional alleles of CYP2C19 and CYP3A4 genes.
The in vitro studies of Pristimerin (PTM) with CYP isoforms indicate that PTM has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, 3A4 and 2C9.
Apigenin showed reversible inhibition, acacetin, and chrysin showed combined irreversible and reversible inhibition while chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin showed pure irreversible inhibition. These results alert on possible flavonoiddrug interactions on the level of CYP3A4
This patient should be regarded as a CYP3A-poor metabolizer.
spectroscopic studies clarified the heteroactivation of CYP3A4 caused by efavirenz with a proper affinity to the peripheral site
The genetic polymorphisms of the multi-drug resistance-1 (MDR-1) and human cytochrome P450 3A (CYP3A4 and CYP3A5) genes were analyzed and compared between steroid sensitive, steroid resistant and control groups.
this meta-analysis suggests that the CYP3A4*1B polymorphism might play a modest role in susceptibility to cancer, especially for leukemia.
JNK is a novel mechanistic regulator of CYP3A4 induction by PXR.
The other four metabolites were almost exclusively metabolized by CYP3A4.
It observed an increase in the activity of CYP3A following but not during pregnancy when measured using the 4beta-hydroxycholesterol/cholesterol ratio. In addition, based on our results, it suggestes that the plasma 4beta-hydroxycholesterol/cholesterol ratio be used to measure CYP3A activity in pregnant women.
These findings also suggest that EGF may be an important regulator of CYP3A4 expression in vivo.
our results indicate that a significant level of MDR1 mRNA, but not CYP3A4 mRNA, is intrinsically present before chemotherapy in advanced STS tumors.
A weak-to-moderate CYP3A4 induction by midostaurin.
CYP3A4 *18B and GCK G-30A polymorphisms were related to new-onset diabetes after transplantation (p < 0.05). The lower concentration/dose or fasting serum glucose was in CYP3A4 *1/*1 carriers than that in *18B/*18B carriers in all the renal transplant recipients (p < 0.05), respectively.
Data suggest high similarity in mechanisms involved in regulation of expression of pig CYP3A29 and human CYP3A4 in hepatocytes.
rs7668282 (UGT2B7, T>C) was more prevalent in sodium valproate (VPA)-resistant patients than drug-responsive patients. rs2242480 (CYP3A4, C>T) and rs10188577 (SCN1A, T>C) were more prevalent in drug-responsive patients compared to drug-resistant patients. In children with generalized seizures on VPA therapy, polymorphisms of UGT2B7, CYP3A4, and SCN1A genes were associated with seizure reduction.
It was concluded that CYP3A related metabolism in horse is not solely dependent on the expression of the enzyme but also on adequate levels of NADPH P450 reductase and cytochrome b(5).
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. This enzyme is involved in the metabolism of approximately half the drugs in use today, including acetaminophen, codeine, cyclosporin A, diazepam and erythromycin. The enzyme also metabolizes some steroids and carcinogens. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Previously another CYP3A gene, CYP3A3, was thought to exist\; however, it is now thought that this sequence represents a transcript variant of CYP3A4. Alternatively spliced transcript variants encoding different isoforms have been identified.
, P450-III, steroid inducible
, albendazole monooxygenase
, albendazole sulfoxidase
, cytochrome P450 3A3
, cytochrome P450 3A4
, cytochrome P450 HLp
, cytochrome P450 NF-25
, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3
, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4
, cytochrome P450-PCN1
, glucocorticoid-inducible P450
, nifedipine oxidase
, quinine 3-monooxygenase
, taurochenodeoxycholate 6-alpha-hydroxylase
, cytochrome P450, family 3, subfamily A, polypeptide 4
, cytochrome P450 3A80
, Cytochrome P450 CM3A-10
, cytochrome P450 3A21
, cytochrome P450 CYP3A12